PN-477sc / Protagonist Therap - LARVOL DELTA

Wholly-Owned Clinical and Discovery Programs (ACCESS Newswire) - "(i) PN-477 (triple GLP1/GIP/GCG agonist peptide for obesity): Phase 1 study with the injectable (sc) PN-477 has begun, and initiation of a Phase 1 study with the oral (o) formulation of PN-477 is anticipated in first half of 2027; (ii) PN-458o (dual GLP/GIP agonist peptide): IND-enabling studies are ongoing with Phase 1 initiation anticipated in the second half of 2027."

New P1 trial • Preclinical • Trial status • Obesity